Analysts Set Evolus, Inc. (NASDAQ:EOLS) PT at $16.00

Evolus, Inc. (NASDAQ:EOLS) has earned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.00.

A number of equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Mizuho set a $15.00 price target on shares of Evolus in a research report on Wednesday, February 4th. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Finally, Stifel Nicolaus lowered their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, January 13th.

Insiders Place Their Bets

In other news, insider Rui Avelar sold 29,996 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $146,680.44. Following the transaction, the insider directly owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Moatazedi sold 116,720 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $570,760.80. Following the transaction, the insider directly owned 618,369 shares in the company, valued at $3,023,824.41. This trade represents a 15.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 163,504 shares of company stock worth $797,184. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Evolus

Institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers grew its holdings in Evolus by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock worth $784,000 after acquiring an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after acquiring an additional 1,838 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Evolus by 7.5% during the second quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after purchasing an additional 2,383 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after purchasing an additional 2,837 shares during the period. Finally, Manchester Capital Management LLC bought a new stake in shares of Evolus in the second quarter worth about $26,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Stock Performance

Shares of NASDAQ:EOLS opened at $4.01 on Friday. The firm has a market capitalization of $260.89 million, a PE ratio of -4.95 and a beta of 1.02. Evolus has a 52-week low of $3.98 and a 52-week high of $12.51. The firm has a fifty day moving average of $4.69 and a 200 day moving average of $5.92.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million. On average, sell-side analysts forecast that Evolus will post -0.61 EPS for the current fiscal year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.